IPHA

Innate Pharma ADR

1.50

Oct 29 • 3:59 PM ET -0.02 (-1.32%)

1.48

Aftermarket • 5:00 PM ET -0.02 (-1.33%)

Healthcare Biotechnology France Micro NASD

Oct 27, 2:12 AMInnate Pharma: AstraZeneca delays PACIFIC-9 Phase 3 durvalumab plus monalizumab data readout to 1H 2027 from 2H 2026

Peers: ALXO BCYC AGEN NKTX XNCR CRVS CUE CMPX CTOR ZYME

Scroll to Statements

Index	-
Market Cap	167.55M
Enterprise Value	178.19M
Income	-55.35M
Sales	4.94M
Book/sh	-0.49
Cash/sh	0.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	163
IPO	Oct 17, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	33.92
P/B	-
P/C	13.45
P/FCF	-
EV/EBITDA	-
EV/Sales	36.07
Quick Ratio	0.60
Current Ratio	0.60
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.59
EPS next Y	-0.15
EPS next Q	-0.15
EPS this Y	73.31%
EPS next Y	14.38%
EPS next 5Y	-
EPS past 3/5Y	6.86% 7.69%
Sales past 3/5Y	-60.77% -45.26%
EPS Y/Y TTM	1.17%
Sales Y/Y TTM	-24.21%
EPS Q/Q	8.99%
Sales Q/Q	99.10%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	18.13% 2.38%

Insider Own	-
Insider Trans	-
Inst Own	0.17%
Inst Trans	4.27%
ROA	-74.40%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-1257.04%
Profit Margin	-1121.55%
SMA20	-0.69%
SMA50	-15.65%
SMA200	-12.58%
Trades

Shs Outstand	93.90M
Shs Float	-
Short Float	-
Short Ratio	0.81
Short Interest	0.13M
52W High	2.71 -44.65%
52W Low	1.17 28.21%
Volatility	5.90% 6.40%
ATR (14)	0.10
RSI (14)	43.06
Beta	0.77
Rel Volume	0.03
Avg Volume	157.35K
Volume	5,395

Perf Week	0.00%
Perf Month	-7.98%
Perf Quarter	-14.29%
Perf Half Y	4.17%
Perf YTD	-14.29%
Perf Year	-27.54%
Perf 3Y	-39.52%
Perf 5Y	-74.14%
Perf 10Y	-
Recom	1.00
Target Price	6.73
Prev Close	1.52
Price	1.50
Change %	-1.32%

Consensus

Strong Buy

Avg. Price Target

$6.73

Implied Upside

+348.7%

Analysts5incl. previous ratings

Rating Distribution3 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 11, 2026	Upgrade	LLeerink Partners	Market Perform → Outperform	$4	+166.7%
Mar 12, 2026	Resumed	BBTIG Research	Buy	$8	+433.3%
Sep 18, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform
Sep 18, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral
Jul 28, 2025	Initiated	BBTIG Research	Buy	$8	+433.3%
Sep 03, 2021	Upgrade	SSVB Leerink	Mkt Perform → Outperform	$7	+366.7%
Dec 15, 2020	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$7 → $5	+233.3%
Nov 24, 2020	Initiated	GGoldman	Neutral	$4.75	+216.7%

Oct-27-26 02:00AM	Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 (Business Wire)
Oct-21-26 01:00AM	Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference (Business Wire)
Oct-20-26 01:00AM	Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update (Business Wire) +8.08%
Sep-17-26 01:00AM	Innate Pharma Reports First Half 2026 Business Update and Financial Results (Business Wire)
Sep-16-26 11:28PM	Sobi and Innate announce partnership is now effective following completion of closing conditions (PR Newswire) +8.06%
04:00PM	Loading…
04:00PM	Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions (Business Wire)
Sep-10-26 01:00AM	Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update (Business Wire)
Sep-02-26 01:00AM	Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Aug-17-26 01:32PM	Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ... (GuruFocus.com)
Aug-14-26 05:30AM	Innate Pharma Announces Conference Call and Webcast (Business Wire) -14.00%
Aug-10-26 08:14AM	Sobi licenses Innates CTCL drug for up to $580m as it heads to Phase III (Pharmaceutical Technology) +28.32%
02:30AM	Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer (Business Wire)
02:00AM	Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma (Business Wire)
Jul-23-26 01:00AM	Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-21-26 01:00AM	Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) (Business Wire)
01:00AM	Loading…
May-22-26 01:00AM	Outcome of Innate Pharmas 2026 Annual General Meeting (Business Wire) -7.11%
May-19-26 01:00AM	Innate Pharma to participate in the Jefferies Global Healthcare Conference (Business Wire) -9.78%
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire) +11.39%
May-13-26 01:00AM	Innate Pharma Reports First Quarter 2026 Business Update and Financial Results (Business Wire)
May-12-26 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026 (Business Wire)
May-06-26 01:00AM	Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update (Business Wire) +7.86%
Apr-23-26 01:00AM	Innate Pharma to Participate in the D. Boral Capital Global Conference (Business Wire)
Apr-17-26 03:00PM	Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 (Business Wire)
Apr-13-26 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 (Business Wire)
Apr-08-26 01:00AM	Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event (Business Wire) +7.41%
Apr-03-26 01:00AM	Innate Pharma to Participate in the Kempen Life Sciences Conference (Business Wire)
Apr-02-26 04:00AM	Innate Pharma Files Its 2025 Universal Registration Document (Document Denregistrement Universel) and 2025 Form 20-f Annual Report (Business Wire)
Mar-26-26 03:00PM	Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
02:00AM	Innate Pharma Reports Full Year 2025 Financial Results and Business Update (Business Wire)
Mar-19-26 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results (Business Wire)
01:00AM	Loading…
Feb-19-26 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 (Business Wire)
Feb-18-26 01:00AM	Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference (Business Wire)
Dec-22-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 (Business Wire)
Dec-11-25 01:00AM	Innate Pharma Releases Its 2026 Financial Calendar (Business Wire)
Nov-28-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 (Business Wire)
Nov-17-25 01:00AM	Innate Pharma to Present at Jefferies Global Healthcare Conference (Business Wire)
Nov-13-25 01:00AM	Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results (Business Wire) -5.21%
Nov-10-25 01:00AM	Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL (Business Wire) +29.56%
Nov-06-25 09:55AM	Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-05-25 01:00AM	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates (Business Wire)
Oct-14-25 01:00AM	Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly) -5.37%
03:00AM	Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com)
Sep-17-25 01:00AM	Innate Pharma Reports First Half 2025 Business Update and Financial Results (Business Wire)
Sep-16-25 09:15AM	Innate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Sep-15-25 01:00AM	Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event (Business Wire)
Sep-10-25 04:30AM	Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update (Business Wire)
Sep-02-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 (Business Wire)
Aug-04-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025 (Business Wire)
Jul-29-25 01:00AM	Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-04-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025 (Business Wire)
Jun-17-25 01:00AM	Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences (Business Wire)
Jun-13-25 01:00AM	Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress (Business Wire)
May-27-25 01:00AM	Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences (Business Wire)
May-23-25 01:00AM	Outcome of Innate Pharmas 2025 Annual General Meeting (Business Wire)
01:00AM	Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides (Business Wire)
May-19-25 01:00AM	Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting (Business Wire)
May-15-25 01:00AM	Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress (Business Wire)
May-13-25 01:00AM	Innate Pharma Reports First Quarter 2025 Business Update and Financial Results (Business Wire) -12.07%
May-12-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025 (Business Wire)
May-06-25 01:00AM	Innate Pharma announces conference call and webcast for Q1 2025 business update (Business Wire)
Apr-30-25 11:30AM	Innate Pharma Files Its 2024 Universal Registration Document (Document denregistrement universel) and 2024 Annual Report on Form 20-F (Business Wire)
Apr-29-25 03:00PM	Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting (Business Wire) +5.26%
Apr-28-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025 (Business Wire) +5.56%
Apr-24-25 01:35AM	Innate Pharma Announces 15M Investment by Sanofi (Business Wire)
Apr-23-25 01:00AM	Innate Pharma Regains Its Rights on CD123 Targeting ANKET and Announces Sanofis Intention to Make a Strategic Investment in the Company (Business Wire)
Apr-16-25 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025 (Business Wire)
01:00AM	Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition (Business Wire)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-03-25 01:00AM	Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum (Business Wire) +7.26%
Mar-27-25 04:49PM	Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript (SeekingAlpha) +8.84%
02:00AM	Innate Pharma Reports Full Year 2024 Financial Results and Business Update (Business Wire)
Mar-26-25 02:00AM	Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting (Business Wire) -8.12%
Mar-25-25 02:00AM	Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference (Business Wire)
Mar-21-25 09:10AM	Innate Pharma: Moving Into The Padcev Space (SeekingAlpha)
Mar-20-25 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results (Business Wire)
Feb-27-25 01:00AM	Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-17-25 01:02AM	Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Szary Syndrome (Business Wire)
Jan-27-25 01:00AM	Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors (Business Wire)
Jan-21-25 01:00AM	Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York (Business Wire)
Jan-16-25 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024 (Business Wire)
Jan-10-25 01:00AM	Innate Pharma Announces Transformative Strategy to Accelerate Growth (Business Wire)
Dec-20-24 01:00AM	Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.09%
Dec-10-24 06:30AM	Innate Pharma SA Reveals Promising Lacutamab Trial Results (TipRanks) -5.26%
Dec-09-24 01:00AM	Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma (Business Wire) +29.25%
Dec-06-24 01:00AM	Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma (Business Wire)
Dec-03-24 01:00AM	Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 (Business Wire)
Nov-20-24 01:00AM	Innate Pharma Releases Its 2025 Financial Calendar (Business Wire) +13.12%
Nov-19-24 01:00AM	Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 (Business Wire)
Nov-13-24 01:00AM	Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results (Business Wire) -11.82%
Nov-08-24 01:00AM	Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 (Business Wire)
Nov-07-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates (Business Wire) -10.45%
Oct-29-24 02:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Business Wire) +8.19%
Oct-14-24 01:00AM	Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board (Business Wire)
Sep-30-24 01:00AM	Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 (Business Wire)
Sep-23-24 01:00AM	Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors (Business Wire)
Sep-12-24 01:00AM	Innate Pharma Reports First Half 2024 Business Update and Financial Results (Business Wire)
Sep-09-24 01:00AM	Innate Pharma SA:Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Business Wire)
Sep-05-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update (Business Wire)
Sep-04-24 01:00AM	Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)

Show Previous News

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.

M.B.A.Mr. Jonathan E. Dickinson B.Sc.

Executive VP & COOMr. Yannis Morel Ph.D.

FounderDr. Francois Romagne Ph.D.

FounderDr. Marc Bonneville Ph.D.

FounderMr. Jean Jacques Fournie Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPHA

Innate Pharma ADR

Upgrade your Finviz experience